AML 50 mg bid (approx 12-hr intervals) on days 8-21 of induction & consolidation chemotherapy cycles & then bid as single agent maintenance for 12 mth.
Patients w/ Grade 4 neutropenia (ANC <0.5 x 109/L) Interrupt treatment until ANC ≥1 x 10
9/L, then resume Rydapt at 50 mg bid.
Advanced SM Initially 100 mg bid. Treatment should be continued as long as clinical benefit is observed or until unacceptable toxicity occurs.
Patients w/ ANC <1 x 109/L who did not have severe neutropenia at baseline Interrupt Rydapt until ANC ≥1.5 x 10
9/L, then resume at 50 mg bid, & if tolerated, gradually increase to 100 mg bid.
Patients w/ Grade 3/4 nausea &/or vomiting despite optimal anti-emetic therapy Interrupt treatment for 3 days (6 doses), then resume Rydapt at 50 mg bid & if tolerated gradually increase to 100 mg bid.
Sign Out
